Hantavirus vaccine in 2026?

Traders currently price "No" at 95% for "Hantavirus vaccine in 2026? ". The market has traded $130K in total volume and resolves Dec 31, 2026. Early-stage research and extended clinical timelines underpin the 94.5% market-implied odds against a hantavirus vaccine reaching approval in 2026. Multiple candidates, including mRNA and DNA platforms targeting glycoproteins of viruses like Andes or Hantaan, remain in preclinical or Phase 1 stages with ongoing safety and immunogenicity studies, while no Phase 3 trials are active. Hantavirus pulmonary syndrome remains rare, constraining large-scale efficacy testing and regulatory pathways. Historical data show inactivated vaccines limited to specific Asian regions without broad modern licensure. Accelerated approval from a major outbreak or unexpected trial acceleration could shift outcomes, though standard vaccine development cycles make such scenarios improbable before year-end.

Odds sourced live from Polymarket, refreshed through the day. Prediction-market participation carries risk and may be restricted in your jurisdiction. Informational only — not investment advice.